NCT05901935 2023-06-13
DP303c in Patients With HER2-positive Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital